Potential treatment for acute respiratory distress syndrome (ARDS) boosted a Canada-listed biotech stock Friday. Here’s some small stocks making big moves on Friday, March 13, 2020 (as of 4 pm EST):
Lattice Biologics Ltd. (TSXV:LBL), a Canada-listed biotech stock, jumped 200% to $0.075 on Friday after announcing that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, which the Company believes has potential for use in the treatment with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).
As well, units of Nexus Real Estate Investment Trust (TSXV:NXR.UN) gained 10% to $1.88 as the real estate investment trust focused on North American industrial, office and retail properties said its 2019 net income increased 9.2% to $42.4 million.
WELL Health Technologies Corp. (TSX:WELL), meanwhile, reported that it is rapidly ramping up efforts on its recently-launched VirtualClinic+ telehealth service due to the anticipated demand for health services generated by the COVID-19 pandemic. WELL Health Technologies stock moved up 3% to $1.39 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Lattice Biologics Ltd. (TSXV:LBL), a Canada-listed biotech stock, jumped 200% to $0.075 on Friday after announcing that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, which the Company believes has potential for use in the treatment with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).
, on Friday.){kind=link}